Levetiracetam Noridem

Levetiracetam, the active ingredient in Levetiracetam Noridem, is an Anticonvulsant presented as an intravenous solution for Intravenous use. It is employed to manage epilepsy by reducing the frequency of seizures in both adult and pediatric patients. It is administered under medical supervision and is available in a sterile formulation suitable for intravenous infusion.

GNH USA supplies Levetiracetam Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide, ensuring consistent quality and regulatory compliance across EU and global markets.

Levetiracetam is an antiepileptic drug used as adjunctive therapy for several seizure types.

- Partial‑onset seizures: provides adjunctive seizure control in patients whose seizures are not fully managed by other medications. - Myoclonic seizures: reduces frequency of myoclonic jerks in patients with juvenile myoclonic epilepsy. - Primary generalized tonic‑clonic seizures: contributes to seizure reduction when added to existing regimens for generalized tonic‑clonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Fatigue: generalized tiredness or lack of energy. - Headache: mild to moderate cranial pain. - Irritability: mood changes including agitation or aggression.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Mood or behavioral changes: depression, suicidal thoughts, or aggression. - Hematologic abnormalities: low blood cell counts such as neutropenia.

When using Levetiracetam, clinicians should consider several safety aspects.

- Renal impairment: adjust dosing and monitor renal function. - Hepatic dysfunction: use with caution in patients with liver disease. - Concomitant CNS depressants: may enhance sedation; observe patient response. - Pregnancy and lactation: limited data; weigh benefits against potential risks. - Behavioral monitoring: watch for mood changes, especially in pediatric patients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: can lower levetiracetam exposure. - Rifampin: induces metabolism, decreasing efficacy.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam concentrations. - Opioids (e.g., tramadol): additive CNS depression risk. - Alcohol: enhances dizziness and sedation.